2660 Patton Road
40 articles with Rebiotix
Rebiotix, C. Diff Foundation Commend State of Minnesota for Declaring November Clostridium difficile Awareness Month
Proclamation heightens public awareness and impact of the devastating infection.
With a growing body of science linking gut microbiota to inflammatory bowel disease (IBD), a need exists in clinical settings to understand changes in the gut microbial community as they relate to IBD and its management.
Rebiotix Clinical, Microbiome Data From First-In-Class Microbiota Restoration Therapy to Be Presented at IDWeek 2018
New data continues to underscore company leadership in microbiome field.
Arc Bio launched its proprietary antimicrobial resistance (AMR) software. It is the first in what it expects to be a series of next-generation sequencing (NGS)-based products for pathogen detection.
FDA’s Approval of T2 Biosystems T2Bacteria Panel Underlines Importance of Sepsis Diagnosis and Tr...
7/10/2018On May 29, the FDA cleared T2 Biosystems’ T2Bacteria Panel for diagnosis of sepsis. In that sepsis is the third-leading cause of death in the U.S., this emphasizes the importance of work in this area.
Microbiome Health Index™ Platform, Outcomes of Rebiotix's RBX7455 Oral Formulation To Be Featured in Rapid Fire and Poster Sessions at ASM Microbe 2018
Microbiome Health Index™ analysis of RBX7455 reveals results similar to those seen in RBX2660 clinical trials
Rebiotix Microbiota Restoration Therapy™ Products, Microbiome Health Index™ to Take Center Stage at Digestive Disease Week 2018
Rebiotix Inc. announced that data analyses from clinical studies of the company's first two Microbiota Restoration Therapy™ products, RBX7455 and RBX2660, as well as ongoing Microbiome Health Index™ research, will be presented in two podium presentations and one poster presentation during the Digestive Disease Week 2018 (DDW2018) meeting.
Rebiotix's President and CEO, Lee Jones to Participate in Microbiome-Focused Panel at the 2018 BIO International Convention
Panel to feature discussions about current experiences in microbiome drug development and the promising future of microbiome therapies
On May 1, the U.S. Food and Drug Administration (FDA) granted Scynexi’s oral formulation of SCY-078 to treat vulvovaginal candidiasis (VVC) and recurrent VVC both Qualified Infectious Diseases Product (QIDP) and Fast Track Designation.
Rebiotix Presents Posters at ECCMID 2018 Highlighting Microbiome Health Index™ Value Potential and RBX2660 Phase 2 Clinical Program Data
The posters add to the growing library of data recently published and presented by Rebiotix highlighting the company's microbiome drug products, clinical programs, and pioneering research involving microbiome composition and health.
Ferring Pharmaceuticals is buying Rebiotix. As part of the deal, will acquire Rebiotix’s lead program, RBX2660, a non-antibiotic treatment to prevent recurring Clostridium difficile infection (CDI).
Rebiotix’s RBX2660 is a non-antibiotic treatment in Phase 3 development for the prevention of recurrent Clostridium difficile infection (CDI) and has the potential to be the world’s first approved human microbiome product
Rebiotix's Chief Scientific Officer, Ken Blount, Ph.D., to Present at Microbiome Therapeutics Europe
Presentation to highlight clinical, regulatory and business opportunities in developing microbiome-directed therapeutics
Initial research indicates that Microbiome HealtMHI was established in partnership with data analytics firm, BioRankings, to enable a non-biased comparison of the efficacy of microbiome-based therapeutics.
Rebiotix provided a review of its 2017 key business achievements and clinical activities as the company anticipates multiple milestones during 2018 involving its industry-leading MRT drug platform.
Rebiotix and CoreBiome Collaborate on Evaluating Microbiomes of Patients Treated With Microbiota Restoration Therapy
Rebiotix, announced today its successful first phase of collaboration with CoreBiome to measure the ability of RBX2660 and RBX7455 to rehabilitate the human microbiome impacted by recurrent Clostridium difficile infection.
Rebiotix Announces Expansion of Phase I Trial of the Company's Oral Capsule Microbiota Product, RBX7455, Following Successful Completion of Initial Study Arms
The expansion follows the successful completion of the study's two initial cohorts and is intended to explore reduced dosing regimens of RBX7455 in two new treatment arms.
New Clinical Data And Microbiome Research From Rebiotix's Phase II Program For RBX2660 Highlighted At The World Congress Of Gastroenterology At ACG2017
Rebiotix today announced new clinical findings from the RBX2660 Phase 2 program that are being presented in three poster presentations at the World Congress of Gastroenterology at ACG2017 in Orlando, Fl.